Gilead Sciences, Inc. (NASDAQ:GILD) EVP James R. Meyers sold 100,000 shares of the stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $80.24, for a total transaction of $8,024,000.00. Following the completion of the sale, the executive vice president now owns 102,715 shares of the company’s stock, valued at $8,241,851.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shares of Gilead Sciences, Inc. (GILD) traded down $0.57 during mid-day trading on Thursday, reaching $81.17. 7,474,993 shares of the company’s stock traded hands, compared to its average volume of 8,130,000. The company has a current ratio of 3.68, a quick ratio of 3.56 and a debt-to-equity ratio of 1.10. The stock has a market capitalization of $106,000.00, a price-to-earnings ratio of 9.23, a PEG ratio of -1.71 and a beta of 1.13. Gilead Sciences, Inc. has a one year low of $63.76 and a one year high of $86.27.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.13 by $0.14. The company had revenue of $6.51 billion during the quarter, compared to analyst estimates of $6.40 billion. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. Gilead Sciences’s revenue was down 13.2% compared to the same quarter last year. During the same quarter last year, the firm posted $2.75 earnings per share. sell-side analysts anticipate that Gilead Sciences, Inc. will post 8.53 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, December 28th. Stockholders of record on Friday, December 15th were paid a $0.52 dividend. This represents a $2.08 annualized dividend and a dividend yield of 2.56%. The ex-dividend date was Thursday, December 14th. Gilead Sciences’s payout ratio is 23.66%.

Hedge funds and other institutional investors have recently bought and sold shares of the company. FMR LLC boosted its stake in shares of Gilead Sciences by 1.1% in the second quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock valued at $1,630,581,000 after purchasing an additional 258,005 shares during the period. Vanguard Group Inc. boosted its stake in shares of Gilead Sciences by 2.4% in the second quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock valued at $6,571,355,000 after purchasing an additional 2,148,697 shares during the period. Northern Trust Corp boosted its stake in shares of Gilead Sciences by 0.7% in the second quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock valued at $1,162,949,000 after purchasing an additional 116,780 shares during the period. Toronto Dominion Bank boosted its stake in shares of Gilead Sciences by 19.0% in the second quarter. Toronto Dominion Bank now owns 472,577 shares of the biopharmaceutical company’s stock valued at $33,445,000 after purchasing an additional 75,364 shares during the period. Finally, Fagan Associates Inc. boosted its stake in shares of Gilead Sciences by 2.6% in the second quarter. Fagan Associates Inc. now owns 33,075 shares of the biopharmaceutical company’s stock valued at $2,341,000 after purchasing an additional 845 shares during the period. 75.95% of the stock is owned by institutional investors and hedge funds.

GILD has been the subject of several recent analyst reports. Vetr upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.98 price objective for the company in a research report on Friday, October 13th. Berenberg Bank set a $96.00 price objective on shares of Gilead Sciences and gave the stock a “buy” rating in a research report on Thursday, October 19th. BMO Capital Markets cut their price objective on shares of Gilead Sciences from $89.00 to $83.00 and set an “outperform” rating for the company in a research report on Friday, October 27th. Credit Suisse Group restated a “buy” rating and set a $82.00 price objective on shares of Gilead Sciences in a research report on Thursday, December 7th. Finally, Mizuho raised their price objective on shares of Gilead Sciences from $77.00 to $83.00 and gave the stock a “buy” rating in a research report on Wednesday, November 8th. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating and eighteen have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $85.53.

TRADEMARK VIOLATION WARNING: “Gilead Sciences, Inc. (GILD) EVP James R. Meyers Sells 100,000 Shares” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2018/01/18/gilead-sciences-inc-gild-evp-james-r-meyers-sells-100000-shares.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Insider Buying and Selling by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.